PL381358A1 - Sposoby i związki pośrednie - Google Patents

Sposoby i związki pośrednie

Info

Publication number: PL381358A1
Authority: PL; Poland
Prior art keywords: indirec; compounds; methods; indirec compounds
Prior art date: 2004-03-12

Application number

PL381358A

Other languages

English (en)

Inventor

Gerald J. Tanoury

Minzhang Chen

Andrew D. Jones

Philip L. Nyce

Martin Trudeau

David J. Guerin

John R. Snoonian

Original Assignee

Vertex Pharmaceuticals Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-12

Filing date

2005-03-11

Publication date

2007-05-28

2005-03-11 Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated

2007-05-28 Publication of PL381358A1 publication Critical patent/PL381358A1/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
- C07B43/04—Formation or introduction of functional groups containing nitrogen of amino groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Catalysts (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Pyrrole Compounds (AREA)

PL381358A 2004-03-12 2005-03-11 Sposoby i związki pośrednie PL381358A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US55248004P	2004-03-12	2004-03-12

Publications (1)

Publication Number	Publication Date
PL381358A1 true PL381358A1 (pl)	2007-05-28

Family

ID=34962478

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL11178128T PL2399916T3 (pl)	2004-03-12	2005-03-11	Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy
PL381358A PL381358A1 (pl)	2004-03-12	2005-03-11	Sposoby i związki pośrednie
PL11178126T PL2399915T3 (pl)	2004-03-12	2005-03-11	Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy
PL05728092T PL1725548T3 (pl)	2004-03-12	2005-03-11	Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL11178128T PL2399916T3 (pl)	2004-03-12	2005-03-11	Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL11178126T PL2399915T3 (pl)	2004-03-12	2005-03-11	Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy
PL05728092T PL1725548T3 (pl)	2004-03-12	2005-03-11	Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy

Country Status (21)

Country	Link
US (4)	US7381827B2 (pl)
EP (3)	EP2399916B1 (pl)
JP (2)	JP4898658B2 (pl)
KR (2)	KR101135765B1 (pl)
CN (3)	CN103467459A (pl)
AR (1)	AR048008A1 (pl)
AU (1)	AU2005223767B2 (pl)
BR (1)	BRPI0508609B8 (pl)
CA (3)	CA2559303C (pl)
DK (3)	DK1725548T3 (pl)
ES (3)	ES2533991T3 (pl)
HU (1)	HUE024556T2 (pl)
IL (3)	IL178003A (pl)
PL (4)	PL2399916T3 (pl)
PT (3)	PT1725548E (pl)
RU (2)	RU2433127C2 (pl)
SG (2)	SG150546A1 (pl)
SI (3)	SI2399915T1 (pl)
TW (3)	TW201200508A (pl)
WO (1)	WO2005090334A2 (pl)
ZA (1)	ZA200607605B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ298749B6 (cs)	1996-10-18	2008-01-16	Vertex Pharmaceuticals Incorporated	Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
PE20011350A1 (es)	2000-05-19	2002-01-15	Vertex Pharma	PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
SV2003000617A (es) *	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
PE20050374A1 (es)	2003-09-05	2005-05-30	Vertex Pharma	Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
EP1718639A2 (en) *	2004-02-27	2006-11-08	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
CA2566362C (en) *	2004-05-15	2013-09-10	Vertex Pharmaceuticals Incorporated	Treating seizures using ice inhibitors
US8399615B2 (en)	2005-08-19	2013-03-19	Vertex Pharmaceuticals Incorporated	Processes and intermediates
AR055395A1 (es) *	2005-08-26	2007-08-22	Vertex Pharma	Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en)	2005-08-26	2011-06-21	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
CA2643688A1 (en)	2006-02-27	2007-08-30	Vertex Pharmaceuticals Incorporated	Co-crystals and pharmaceutical compositions comprising the same
WO2007109080A2 (en)	2006-03-16	2007-09-27	Vertex Pharmaceuticals Incorporated	Deuterated hepatitis c protease inhibitors
CN101534824A (zh) *	2006-11-17	2009-09-16	艾博特公司	作为化学活素受体拮抗剂的氨基吡咯烷
WO2008106058A2 (en)	2007-02-27	2008-09-04	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
GEP20125645B (en) *	2007-02-27	2012-09-25	Vertex Pharma	Co-crystals and pharmaceutical compositions comprising the same
WO2009032198A1 (en)	2007-08-30	2009-03-12	Vertex Pharmaceuticals Incorporated	Co-crystals and pharmaceutical compositions comprising the same
US8518942B2 (en)	2008-08-06	2013-08-27	Buck Institute For Research On Aging	Caspase inhibitors and uses thereof
US9113848B2 (en) *	2010-02-03	2015-08-25	Covidien Lp	Surgical retrieval apparatus
JP5769655B2 (ja) *	2012-03-30	2015-08-26	ユニ・チャーム株式会社	吸収性物品
CN103193572B (zh) *	2013-04-07	2015-06-17	山东大学	一种拉唑类化合物单一对映体的分离方法
CN110545835A (zh)	2016-12-23	2019-12-06	A·勒布朗	Caspase-1抑制及其用于预防和治疗神经病症的用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5874424A (en) *	1995-12-20	1999-02-23	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en)	1995-12-20	2001-03-20	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β Converting enzyme inhibitors
GB9123326D0 (en)	1991-11-04	1991-12-18	Sandoz Ltd	Improvements in or relating to organic compounds
BE1008343A3 (nl)	1994-05-06	1996-04-02	Dsm Nv	Bidentaat fosfineligand
US5756466A (en)	1994-06-17	1998-05-26	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) *	1995-06-05	2002-07-16	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β converting enzyme
US5847135A (en)	1994-06-17	1998-12-08	Vertex Pharmaceuticals, Incorporated	Inhibitors of interleukin-1β converting enzyme
US5716929A (en)	1994-06-17	1998-02-10	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1β converting enzyme
ES2150696T3 (es) *	1995-11-09	2000-12-01	Akzo Pq Silica Vof	Silicato de sodio compactado.
US5843904A (en)	1995-12-20	1998-12-01	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1βconverting enzyme
DE69718012T2 (de)	1996-09-12	2003-09-25	Idun Pharmaceuticals, Inc.	C-terminale modifizierte (n-substituierte)-2-indolyl dipeptide als inhibitoren von der ice/ced-3 cysteinprotease familie
DE69734718T2 (de)	1996-09-12	2006-08-24	Idun Pharmaceuticals, Inc., San Diego	Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
US6200969B1 (en) *	1996-09-12	2001-03-13	Idun Pharmaceuticals, Inc.	Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
DE69711845T2 (de)	1996-09-12	2002-10-31	Idun Pharmaceuticals, Inc.	Neue tricyclische verbindungen mit ice/ced-3 protease familie-hemmenden eigenschaften
US5968927A (en) *	1996-09-20	1999-10-19	Idun Pharmaceuticals, Inc.	Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
CA2268098A1 (en)	1996-10-11	1998-04-23	Warner-Lambert Company	Aspartate ester inhibitors of interleukin-1.beta. converting enzyme
US5919790A (en)	1996-10-11	1999-07-06	Warner-Lambert Company	Hydroxamate inhibitors of interleukin-1β converting enzyme
US6316415B1 (en)	1996-10-11	2001-11-13	Basf Aktiengesellschaft	Sulfonamide interleukin-1β converting enzyme inhibitors
CZ298749B6 (cs) *	1996-10-18	2008-01-16	Vertex Pharmaceuticals Incorporated	Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
US6184244B1 (en) *	1996-12-16	2001-02-06	Idun Pharmaceuticals, Inc.	C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
FR2766188B1 (fr) *	1997-07-15	2000-02-11	Hoechst Marion Roussel Inc	Nouveau procede de preparation de derives amines d'alkyloxy furanone, composes issus de ce procede et utilisation de ces composes
US6184210B1 (en) *	1997-10-10	2001-02-06	Cytovia, Inc.	Dipeptide apoptosis inhibitors and the use thereof
ES2302363T3 (es)	1997-12-18	2008-07-01	Boehringer Ingelheim Pharmaceuticals Inc.	Piridonas como inhibidores del dominia sh2 del grupo src.
DK1049703T3 (da)	1998-01-20	2003-06-02	Abbott Gmbh & Co Kg	N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2--(4-fluorphenyl)-1,6-dihydro-1-pyrimidinyl)acetoxyl]-L-asparaginsyrealdehyd som en in vivo inhibitor af interleukin-1beta konverterende enzym
CA2324226C (en) *	1998-03-19	2012-06-05	Vertex Pharmaceuticals Incorporated	Inhibitors of caspases
US6197750B1 (en)	1998-07-02	2001-03-06	Idun Pharmaceuticals, Inc.	C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6323180B1 (en) *	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
US6242422B1 (en) *	1998-10-22	2001-06-05	Idun Pharmacueticals, Inc.	(Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
AU765462B2 (en)	1999-03-16	2003-09-18	Merck Frosst Canada & Co.	Gamma-ketoacid dipeptides as inhibitors of caspase-3
ATE336480T1 (de) *	1999-03-16	2006-09-15	Cytovia Inc	Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
WO2000061542A1 (en) *	1999-04-09	2000-10-19	Cytovia, Inc.	Caspase inhibitors and the use thereof
WO2001005772A1 (en)	1999-07-19	2001-01-25	Merck Frosst Canada & Co.	Pyrazinones, compositions containing such compounds
AU6894800A (en)	1999-08-06	2001-03-05	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
IL148426A0 (en) *	1999-08-27	2002-09-12	Cytovia Inc	α-HYDROXY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
AR026748A1 (es)	1999-12-08	2003-02-26	Vertex Pharma	Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
YU73702A (sh)	2000-03-29	2006-03-03	Vertex Pharmaceuticals Incorporated	Karbamatni inhibitori kaspaze i njihova upotreba
JP4806154B2 (ja) *	2000-04-03	2011-11-02	バーテックスファーマシューティカルズインコーポレイテッド	セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
DE60142470D1 (de) *	2000-04-24	2010-08-12	Vertex Pharma	Verfahren und zwischenprodukte zur herstellung von substituierten asparaginsäure-acetalen
TWI291462B (en) *	2000-04-25	2007-12-21	Daiichi Sankyo Co Ltd	Hydrate crystal of neuraminic acid compound
PE20011350A1 (es) *	2000-05-19	2002-01-15	Vertex Pharma	PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
EP1283827A2 (en)	2000-05-23	2003-02-19	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
EP1289993B9 (en)	2000-06-07	2008-08-20	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
MXPA03000627A (es) *	2000-07-21	2004-07-30	Schering Corp	Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
US6800619B2 (en)	2000-09-13	2004-10-05	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
US6846806B2 (en) *	2000-10-23	2005-01-25	Bristol-Myers Squibb Company	Peptide inhibitors of Hepatitis C virus NS3 protein
JP4349802B2 (ja) *	2000-11-21	2009-10-21	バーテックスファーマシューティカルズインコーポレイテッド	イミダゾールおよびベンゾイミダゾールカスパーゼのインヒビターならびにそれらの使用
GB0107924D0 (en) *	2001-03-29	2001-05-23	Angeletti P Ist Richerche Bio	Inhibitor of hepatitis C virus NS3 protease
EP1381602A1 (en) *	2001-04-19	2004-01-21	Vertex Pharmaceuticals Incorporated	Heterocyclyldicarbamides as caspase inhibitors
JP4428926B2 (ja)	2001-05-23	2010-03-10	バーテックスファーマシューティカルズインコーポレイテッド	カスパーゼインヒビターおよびそれらの使用
CA2449504A1 (en) *	2001-07-11	2003-01-23	Vertex Pharmaceuticals Incorporated	Bridged bicyclic serine protease inhibitors
AU2002348533A1 (en) *	2001-10-09	2003-05-26	Vertex Pharmaceuticals Incorporated	Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof
US7410956B2 (en) *	2002-02-11	2008-08-12	Vertex Pharmaceuticals Incorporated	Caspase inhibitor prodrugs
US7960398B2 (en) *	2002-04-19	2011-06-14	Vertex Pharmaceuticals Incorporated	Regulation of TNF-alpha
US7001899B2 (en)	2002-06-10	2006-02-21	The Procter & Gamble Company	Interleukin converting enzyme inhibitors
US7138395B2 (en)	2002-06-10	2006-11-21	The Procter & Gamble Company	Interleukin-1β converting enzyme inhibitors
US7041696B2 (en)	2002-06-17	2006-05-09	The Procter & Gamble Company	Interleukin-1β converting enzyme inhibitors
BR0312232A (pt) *	2002-06-28	2005-05-10	Vertex Pharma	Inibidores de caspases e seus usos
EP1581501A1 (en)	2002-12-20	2005-10-05	Vertex Pharmaceuticals Incorporated	4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
PE20050159A1 (es)	2003-05-27	2005-04-19	Vertex Pharma	Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
EP1718639A2 (en) *	2004-02-27	2006-11-08	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof

2005
- 2005-03-11 KR KR1020067021136A patent/KR101135765B1/ko not_active Expired - Fee Related
- 2005-03-11 BR BRPI0508609A patent/BRPI0508609B8/pt not_active IP Right Cessation
- 2005-03-11 CA CA2559303A patent/CA2559303C/en not_active Expired - Fee Related
- 2005-03-11 PT PT57280927T patent/PT1725548E/pt unknown
- 2005-03-11 SI SI200531945T patent/SI2399915T1/sl unknown
- 2005-03-11 RU RU2006136032/04A patent/RU2433127C2/ru active
- 2005-03-11 PL PL11178128T patent/PL2399916T3/pl unknown
- 2005-03-11 CN CN2013103410022A patent/CN103467459A/zh active Pending
- 2005-03-11 DK DK05728092.7T patent/DK1725548T3/en active
- 2005-03-11 CN CN2011100999799A patent/CN102225936B/zh not_active Expired - Lifetime
- 2005-03-11 ES ES05728092.7T patent/ES2533991T3/es not_active Expired - Lifetime
- 2005-03-11 JP JP2007503066A patent/JP4898658B2/ja not_active Expired - Lifetime
- 2005-03-11 CA CA2843066A patent/CA2843066C/en not_active Expired - Fee Related
- 2005-03-11 ES ES11178126.6T patent/ES2532967T3/es not_active Expired - Lifetime
- 2005-03-11 CN CN2005800144933A patent/CN1950364B/zh not_active Expired - Lifetime
- 2005-03-11 AU AU2005223767A patent/AU2005223767B2/en not_active Ceased
- 2005-03-11 DK DK11178126T patent/DK2399915T3/en active
- 2005-03-11 ES ES11178128.2T patent/ES2532433T3/es not_active Expired - Lifetime
- 2005-03-11 AR ARP050100964A patent/AR048008A1/es not_active Application Discontinuation
- 2005-03-11 SI SI200531941T patent/SI2399916T1/sl unknown
- 2005-03-11 SG SG200901306-1A patent/SG150546A1/en unknown
- 2005-03-11 DK DK11178128T patent/DK2399916T3/en active
- 2005-03-11 SG SG200901309-5A patent/SG150547A1/en unknown
- 2005-03-11 PT PT111781266T patent/PT2399915E/pt unknown
- 2005-03-11 PT PT11178128T patent/PT2399916E/pt unknown
- 2005-03-11 EP EP11178128.2A patent/EP2399916B1/en not_active Expired - Lifetime
- 2005-03-11 CA CA2768700A patent/CA2768700C/en not_active Expired - Fee Related
- 2005-03-11 PL PL381358A patent/PL381358A1/pl not_active Application Discontinuation
- 2005-03-11 US US11/078,147 patent/US7381827B2/en active Active
- 2005-03-11 HU HUE05728092A patent/HUE024556T2/hu unknown
- 2005-03-11 SI SI200531959T patent/SI1725548T1/sl unknown
- 2005-03-11 EP EP05728092.7A patent/EP1725548B1/en not_active Expired - Lifetime
- 2005-03-11 WO PCT/US2005/008251 patent/WO2005090334A2/en not_active Ceased
- 2005-03-11 PL PL11178126T patent/PL2399915T3/pl unknown
- 2005-03-11 EP EP11178126.6A patent/EP2399915B1/en not_active Expired - Lifetime
- 2005-03-11 PL PL05728092T patent/PL1725548T3/pl unknown
- 2005-03-11 KR KR1020117029981A patent/KR20110137409A/ko not_active Ceased
- 2005-03-14 TW TW100133524A patent/TW201200508A/zh unknown
- 2005-03-14 TW TW094107737A patent/TWI398426B/zh not_active IP Right Cessation
- 2005-03-14 TW TW101124668A patent/TWI399356B/zh not_active IP Right Cessation
2006
- 2006-09-11 IL IL178003A patent/IL178003A/en active IP Right Grant
- 2006-09-11 ZA ZA200607605A patent/ZA200607605B/xx unknown
2008
- 2008-03-07 US US12/074,983 patent/US7834200B2/en not_active Expired - Lifetime
2010
- 2010-10-12 US US12/902,811 patent/US8293929B2/en not_active Expired - Lifetime
2011
- 2011-07-01 RU RU2011127174/04A patent/RU2011127174A/ru not_active Application Discontinuation
- 2011-10-26 JP JP2011235246A patent/JP2012072151A/ja active Pending
2012
- 2012-03-05 IL IL218488A patent/IL218488A0/en unknown
- 2012-03-05 IL IL218487A patent/IL218487A/en active IP Right Grant
- 2012-09-20 US US13/623,563 patent/US20130066083A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1725548B1 (en)	2015-01-14
CN1950364B (zh)	2011-06-08
US20110071298A1 (en)	2011-03-24
CN102225936B (zh)	2013-09-11
BRPI0508609B8 (pt)	2021-05-25
IL178003A0 (en)	2006-12-31
JP2012072151A (ja)	2012-04-12
CN103467459A (zh)	2013-12-25
SI1725548T1 (sl)	2015-05-29
PL1725548T3 (pl)	2015-08-31
DK2399916T3 (en)	2015-03-02
KR20070006835A (ko)	2007-01-11
RU2011127174A (ru)	2013-01-10
CA2768700A1 (en)	2005-09-29
US7834200B2 (en)	2010-11-16
TWI399356B (zh)	2013-06-21
US20090048429A1 (en)	2009-02-19
HK1105955A1 (en)	2008-02-29
ES2532967T3 (es)	2015-04-06
CA2843066C (en)	2016-06-07
ES2533991T3 (es)	2015-04-16
IL218487A0 (en)	2012-04-30
PT2399915E (pt)	2015-03-30
EP1725548A2 (en)	2006-11-29
WO2005090334A3 (en)	2005-11-17
WO2005090334A2 (en)	2005-09-29
RU2433127C2 (ru)	2011-11-10
SI2399916T1 (sl)	2015-05-29
DK1725548T3 (en)	2015-03-23
SG150547A1 (en)	2009-03-30
BRPI0508609A (pt)	2007-07-31
CA2559303A1 (en)	2005-09-29
CA2843066A1 (en)	2005-09-29
SI2399915T1 (sl)	2015-05-29
AR048008A1 (es)	2006-03-15
CA2559303C (en)	2013-09-10
RU2006136032A (ru)	2008-04-20
US8293929B2 (en)	2012-10-23
HUE024556T2 (hu)	2016-02-29
EP2399916B1 (en)	2014-12-10
TW201200508A (en)	2012-01-01
PL2399915T3 (pl)	2015-07-31
KR101135765B1 (ko)	2012-04-23
CA2768700C (en)	2014-04-29
US20130066083A1 (en)	2013-03-14
EP2399915B1 (en)	2014-12-17
CN102225936A (zh)	2011-10-26
US7381827B2 (en)	2008-06-03
EP2399916A1 (en)	2011-12-28
ZA200607605B (en)	2009-04-29
PT1725548E (pt)	2015-04-16
AU2005223767A1 (en)	2005-09-29
IL178003A (en)	2012-04-30
PT2399916E (pt)	2015-03-17
BRPI0508609B1 (pt)	2021-03-30
AU2005223767B2 (en)	2011-12-01
SG150546A1 (en)	2009-03-30
ES2532433T3 (es)	2015-03-26
TWI398426B (zh)	2013-06-11
TW200602341A (en)	2006-01-16
CN1950364A (zh)	2007-04-18
IL218487A (en)	2015-08-31
IL218488A0 (en)	2012-04-30
JP2007528904A (ja)	2007-10-18
US20060020016A1 (en)	2006-01-26
JP4898658B2 (ja)	2012-03-21
TW201247594A (en)	2012-12-01
KR20110137409A (ko)	2011-12-22
DK2399915T3 (en)	2015-03-09
HK1163672A1 (en)	2012-09-14
EP2399915A1 (en)	2011-12-28
PL2399916T3 (pl)	2015-06-30

Legal Events

Date	Code	Title	Description
2014-04-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
EP1802588A4 (en)	2010-02-17	SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
AP2006003810A0 (en)	2006-12-31	4-Phenylamino-quinazolin-6-yl-amides
EP1737565A4 (en)	2010-11-03	COS CLAUS CONFIGURATIONS AND METHODS
DE502005007456D1 (en)	2009-07-23	Nanoemulsionen
IL179497A0 (en)	2011-08-01	Carboranylporphyrins and uses thereof
SG119251A1 (en)	2006-02-28	Methods
DE502005009795D1 (en)	2010-08-05	Modulares gelenkprothesensystem
GB0424552D0 (en)	2004-12-08	Methods and means
IL180365A0 (en)	2007-06-03	Carboranylporphyrins and uses thereof
GB0403629D0 (en)	2004-03-24	Methods
DE502005010653D1 (en)	2011-01-20	Eiten
GB0403847D0 (en)	2004-03-24	Methods and means
GB0423552D0 (en)	2004-11-24	Methods
GB0421911D0 (en)	2004-11-03	Methods and means
GB0408156D0 (en)	2004-05-19	Process and compounds
GB0415757D0 (en)	2004-08-18	Methods
IL165458A0 (en)	2006-01-15	And
GB0421466D0 (en)	2004-10-27	Methods and means
GB0425081D0 (en)	2004-12-15	Methods and means
GB0427483D0 (en)	2005-01-19	Methods and means
GB0419181D0 (en)	2004-09-29	Methods and means
GB0423658D0 (en)	2004-11-24	Methods and means
GB0424494D0 (en)	2004-12-08	Use
SG120191A1 (en)	2006-03-28	Methods
GB0413206D0 (en)	2004-07-14	Methods